KNOWLEDGE BANK

Interviews

Porton Pharma Solutions and Codexis Launch Global Partnership

PARTNERSHIP
Codexis Inc and Porton Pharma Solutions Ltd announce a strategic collaboration to deploy Codexis worldleading biocatalyst technology within Portons global custom intermediate and active pharmaceutical ingredients API development and manufacturing business The partnership will accelerate the creation and commercialization of new lowcost sustainable manufacturing processes exploiting the benefits of...

Articles

Current Research on Plant miRNA and Its Application in Disease Prevention

Natural compounds are becoming more popular as reliable sources of disease prevention due to their lower toxicity ease of availability and minor complications in therapeutic interventions Let food be thy medicine and medicine be thy food Hippocrates said nearly years ago implying that both food consumption and disease occurrence influence an individuals health Aman and Masood Bioactive compounds...

Research Insights

Synergistic Drug Combinations Designed to Fully Suppress SARS-CoV-2 in the Lung of COVID-19 Patients

Despite new antivirals are being approved against SARSCoV they suffer from significant constraints and are not indicated for hospitalized patients who are left with few antiviral options Repurposed drugs have previously shown controversial clinical results and it remains difficult to understand why certain trials delivered

Case Studies

Pediatrician’s Cough And Cold Medication Prescription For Hypothetical Cases: A Cross-Sectional Multi-Centric Case Study

Abstract Cough and cold is the most common cause for hospital visits and so is the use of cough and cold medication CCM A cough and cold medication has been considered to contain a single ingredient SI or multiple ingredients MI like promethazine PRZ chlorpheniramine CPM pseudoephedrine PS phenylephrine PE diphenhydramine DPH dextromethor

Techno Trends

Ascentage Pharma Developed Novel Olverembatinib Drug Candidate to Treat SDH-Deficient GIST

Ascentage Pharma developed olverembatinib HQP novel drug candidate for the treatment of patients with succinate dehydrogenase SDHdeficient gastrointestinal stromal tumour GIST who had obtained firstline treatment

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Artificial Intelligence

Mansi Athalye

Assistant Professor, Department of Pharmaceutics, L. M.College of Pharmacy

Daryai Uma Ghanshyam

L. M.College of Pharmacy

2

Transforming Customer Engagement in Life Sciences Adopting Hybrid Commercial Models (HCMs)

Rohit K

 

 is a Practice Director at the Life Sciences IT Services team, leading commercial technology research and client engagements. He has worked with business and IT leaders on strategy, M&A, and market intelligence. Previously a Consultant at EY, Rohit holds an MBA from FMS, Delhi University, and an engineering degree from NIT Jalandhar.

3

Kinase Inhibitors as Antiviral Agents

Thanigaimalai Pillaiyar

Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.

 

Stefan Laufer

Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.

 

4

Peptide-Drug Conjugates in Precision Oncology

Dr. Keykavous Parang

Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.

Thuy Do

Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.

Clare Dinh

Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.

Mahsa Moazen

Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”

Troy Khong

Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.

5

Beyond the Cold Chain

Dr. Mary Manoranjani Addanki

Dr. Mary Manoranjani Addanki, PhD, is an Associate Professor and Head of Pharmaceutics at Malla Reddy College of Pharmacy. With 17 years of expertise, she specialises in nanotechnology, pulmonary vaccines, and advanced drug delivery. An award-winning researcher and patent holder, her work focuses on stabilising vaccines and developing innovative dosage forms.

press releasesRead more...

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays

Monod Bio a Seattlebased AIenabled protein design company and SignalChem Biotech Inc a whollyowned subsidiary of Sino Biological Inc SZSE today announced a nonexclusive licensing agreement

Lotus Pharmaceutical Announces Favorable U.S. Appeals Court Ruling on Norwich’s Application for Generic Rifaximin

Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange a leading global pharmaceutical company today announced that Norwich Pharmaceuticals Inc Norwich a wholly owned subsidiary of Alvogen

SK Biopharmaceuticals to In-License Epilepsy Drug Candidate ‘Opakalim’ Paves the Way to Launch its Second Innovative Drug Directly in the U.S.

SK Biopharmaceuticals Co Ltd wwwskbpcom CEO Donghoon Lee held a press conference on August th and announced that it has entered into an agreement to inlicense opakalim an investigational

DKSH Performance Materials Expands its Pharma Business Through the Acquisition of P.R. Chemicals in Thailand

DKSH has signed an agreement to acquire PR Chemicals Company Limited PR Chemicals a Thai distributor specialized in Active Pharmaceutical Ingredients APIs

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

Celltrion KRX today announced the launch of the mg strength of Omlyclo omalizumab a treatment for chronic spontaneous urticaria and allergic asthma in Europe With the addition

ASTRI and Saint Francis University Sign MoU to Advance AI-Enabled Biomaterials and Digital Health Innovation

The Hong Kong Applied Science and Technology Research Institute ASTRI and Saint Francis University SFU have signed a Memorandum of Understanding MoU to establish a strategic partnership focused on advancing

EventsRead more...

03 - 05

Sep 2026

5th MENA Congress for Rare Diseases 2026

Beach Rotana Hotel, Abu Dhabi,...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

Jazz Pharmaceuticals Announces Approval of Ziihera Regimens for Advanced HER2-Positive Gastroesophageal Cancer

Jazz Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved two Ziihera zanidatamabhriibased treatment regimens for the firstline treatment of adults with unresectable

BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients

BioCryst Pharmaceuticals has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORLADEYO berotralstat for the prevention of hereditary angioedema HAE attacks in children aged to under years

Takeda Receives Approval for ORZEYFUL (oveporexton) to Treat Narcolepsy Type 1

Takeda has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORZEYFUL oveporexton for the treatment of narcolepsy type NT a form of narcolepsy associated with cataplexy in adults

Johnson & Johnson’s IMAAVY Approved in the US as First Treatment for Warm Autoimmune Haemolytic Anaemia

Johnson Johnson has announced that the US Food and Drug Administration FDA has approved IMAAVY nipocalimabaahu for the treatment of warm autoimmune haemolytic anaemia wAIHA in adults and children aged years and older who are currently or previously treated with corticosteroids

Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan

Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange has received marketing approval in Japan for its generic pomalidomide capsules in mg mg mg and mg strengths following a review

Ultragenyx Receives U.S. FDA Approval for GENGLYCOS Gene Therapy for Glycogen Storage Disease Type Ia

Ultragenyx Pharmaceutical Inc NASDAQ RARE has received accelerated approval from the US Food and Drug Administration FDA for GENGLYCOS pariglasgene brecaparvovecopnr also known as DTX for adults and children aged eight years and older with glycogen storage disease type Ia GSDIa